Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients
about
Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.Cytomegalovirus infection in childhood-onset systemic lupus erythematosus.HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia.Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Early abnormal liver enzyme levels may increase the prevalence of human cytomegalovirus antigenaemia after hematopoietic stem cell transplantation.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation.Immunotherapy for transplantation-associated viral infections.Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Respiratory failure in the hematopoietic stem cell transplant recipient
P2860
Q34750093-1660A11E-D988-4365-9819-8C4C1343D119Q35776868-AEE0296E-8F4A-4A00-95FF-365E301E9754Q37179131-D1C7A953-887E-4B7A-B6C7-03634FD44C5FQ37577044-D50F152F-C592-4921-A420-74AB44E7D04BQ37580837-0A2CC111-F843-4BFF-A6D6-B959559B1E5FQ38281851-37460B1B-6A8E-4C09-A61A-A5349734D390Q38376028-55B0C0BF-4988-429B-8545-DAFAF4304926Q38385536-2AEEB14E-9A12-476E-9BFD-4877163AA7FDQ38617612-26E657E7-7835-4328-927F-9C4D7268F264Q38802522-E2FAE7F0-B352-42F8-AFDD-F7FAA38B2048Q38833951-E78A868A-818F-4B95-8F25-F3DE13561987Q38835171-48C2EA33-D6BE-4D37-8A16-900188DAAD98Q39118448-5EF5350D-CB3C-45F9-B00D-367F870830A7Q39382670-8E560A1C-56D0-4E70-82D1-5235965C9192Q40583652-09748AF8-6F49-42B5-9AD0-31275CEB4595Q40674993-3234F0A2-D6AA-4F45-A090-08AA0294DE80Q40721706-31E4DDC0-C792-43EF-8D46-A6EA48881A1EQ44714539-A1F39AC1-54DE-46EA-ACDC-AE7B741A84E1Q58121933-52923CA0-1F48-4822-B368-6F8D8C3B94AA
P2860
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficiency and risk factors fo ...... topoietic stem cell recipients
@ast
Efficiency and risk factors fo ...... topoietic stem cell recipients
@en
type
label
Efficiency and risk factors fo ...... topoietic stem cell recipients
@ast
Efficiency and risk factors fo ...... topoietic stem cell recipients
@en
prefLabel
Efficiency and risk factors fo ...... topoietic stem cell recipients
@ast
Efficiency and risk factors fo ...... topoietic stem cell recipients
@en
P2093
P2860
P1476
Efficiency and risk factors fo ...... topoietic stem cell recipients
@en
P2093
Jeremy Smith
Louise E Kimball
Margaret Pollack
Michael J Boeckh
Ravinder Sandhu
Steven A Pergam
Terry Stevens-Ayers
Tracy S Hayes
Valeria Ilieva
P2860
P304
P356
10.1016/J.BBMT.2012.02.008
P577
2012-03-03T00:00:00Z